Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE, DATED DECEMBER 15, 2020 - ENDRA Life Sciences Inc. | ndra_ex992.htm |
EX-99.1 - PRESS RELEASE, DATED DECEMBER 15, 2020 - ENDRA Life Sciences Inc. | ndra_ex991.htm |
EX-5.1 - OPINION - ENDRA Life Sciences Inc. | ndra_ex51.htm |
EX-1.1 - UNDERWRITING AGREEMENT, DATED DECEMBER 15, 2020 - ENDRA Life Sciences Inc. | ndra_ex11.htm |
8-K - CURRENT REPORT - ENDRA Life Sciences Inc. | ndra_8k.htm |
Exhibit 99.3
ENDRA Life Sciences
Announces Closing of Public Offering of Common Stock and Exercise
of Over-Allotment Option
ANN ARBOR, MI / ACCESSWIRE / December 18, 2020 /
ENDRA Life
Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a developer of
enhanced ultrasound technologies, today reported the closing of its
previously announced underwritten public offering of 7,143,000
shares of common stock at an offering price of $0.70 per share. In
connection with the offering, the underwriter exercised its
over-allotment option to purchase an additional 714,286 shares of
common stock at the public offering price, less the underwriting
discount, in full. As a result, the total offering size was
7,857,286 shares, and the gross proceeds from the offering were
$5,500,100, before deducting underwriting discounts and estimated
offering expenses. All of the shares of common stock were offered
by ENDRA.
ThinkEquity,
a division of Fordham Financial Management, Inc., acted as the sole
underwriter for the offering.
A shelf
registration statement on Form S-3 (File No. 333-229090) relating
to the shares of common stock issued in the proposed offering was
filed with the Securities and Exchange Commission (the "SEC") and
is effective. The final prospectus supplement relating to the
offering was filed with the SEC on December 17, 2020. Copies of the
final prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from ThinkEquity, a
division of Fordham Financial Management, Inc., 17 State Street,
22nd Floor, New York, New York 10004, by telephone at (877)
436-3673, or by email at prospectus@think-equity.com. Electronic
copies of the final prospectus supplement and accompanying
prospectus are also available on the SEC's website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About ENDRA Life Sciences Inc.
ENDRA
Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound
(TAEUS®), a
ground-breaking technology being developed to visualize tissue like
MRI, but at 1/50th the cost and at the
point of patient care. TAEUS is designed to work in concert with
the over one million ultrasound systems in use globally today.
TAEUS is initially focused on the measurement of fat in the liver
as a means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over 1 billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visitwww.endrainc.com.
Forward-Looking Statements
All
statements in this news release that are not based on historical
fact are "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements, which are based
on certain assumptions and describe our future plans, strategies
and expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "could," "seek," "intend," "plan," "goal," "estimate,"
"anticipate" or other comparable terms. Examples of forward-looking
statements include, among others, estimates of the timing of future
events and achievements, such as the expectations regarding
commercializing the TAEUS device, establishing evaluation reference
sites and initial sales in Europe, receipt of U.S. Food and Drug
Administration regulatory approval and expectations concerning
ENDRA's business strategy. Forward-looking statements involve
inherent risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements as a
result of various factors including, among others, risks relating
to our ability to develop a commercially feasible technology;
receipt of necessary regulatory approvals; the impact of COVID-19
on our business plans; our ability to find and maintain development
partners, market acceptance of our technology and the amount and
nature of competition in our industry; our ability to protect our
intellectual property; and the other risks and uncertainties
described in ENDRA's filings with the Securities and Exchange
Commission. The forward-looking statements made in this news
release speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
Company Contact:
David
Wells
Chief
Financial Officer
(734)
997-0464
investors@endrainc.com
www.endrainc.com
Investor Relations Contact:
Kim
Sutton Golodetz
LHA
Investor Relations
(212)
838-3777
kgolodetz@lhai.com